Articles tagged "Hepatitis C"

2019 American Transplant Congress
Multicenter Experience Evaluating Outcomes of HCV-Seropositive Donors to HCV-Seronegative Recipients Liver Transplantation
K. Wijarnpreecha¹, B. Aqel², S. Pungpapong¹, C. Taner³, K. Reddy⁴, M. Leise⁵, R. Dickson²
¹Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, ²Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, ³Transplant, Mayo Clinic, Jacksonville, FL, ⁴Transplant and Hepatobiliary Surgery, Mayo Clinic, Scottsdale, AZ, ⁵Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
*Purpose: Grafts from hepatitis C virus (HCV)-seropositive donors can now be considered for liver transplant (LT) due to the advent of direct-acting antiviral agents (DAA).…
2019 American Transplant Congress
Hepatitis C Positive Donor to Negative Recipient Kidney Transplantation: A Single Center Real World Experience
N. Jandovitz, V. Nair, E. Grodstein, E. Molmenti, A. Fahmy, M. Bhaskaran, L. Teperman
North Shore University Hospital, Manhasset, NY
*Purpose: Several small studies have shown that transplanting a hepatitis C virus (HCV) negative recipient with a HCV positive donor is feasible in a research…
2019 American Transplant Congress
Real World Impact of HCV Viremic Solid Organs on Waitlist Times
N. Kapila¹, A. Ur Rahman¹, K. Gupta², K. Al Khalloufi³, E. Navas³, D. Reino³, S. Ebaid³, N. Agarwal³, J. Shaw³, C. Murgas³, S. Rhazouani³, A. Zeeshan³, A. Tzakis³, C. Sheffield³, J. Vanatta³, X. Zervos³
¹Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, ²Internal Medicine, University of Miami/JFK Consortium, Atlantis, FL, ³Transplant, Cleveland Clinic Florida, Weston, FL
*Purpose: The advent of direct acting antiviral agents (DAAs) has led to a paradigm shift in the approach to hepatitis C (HCV) infected organs. The…
2019 American Transplant Congress
Rapid Growth of HCV-Infected Donors for HCV-Uninfected Kidney and Liver Transplant Recipients in the United States
M. Bowring, A. Shaffer, A. Massie, N. Desai, M. Sulkowski, A. Cameron, J. Garonzik-Wang, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: Several single-center reports of using HCV-viremic organs for HCV-uninfected recipients were recently published in the US. In light of recent DAA introduction, we sought…
2019 American Transplant Congress
Timing, Duration, and Source of Hepatitis C Virus (HCV) Antibodies (Ab) among HCV-Negative Recipients of an Organ from an HCV-Infected Donor
P. Porrett¹, P. Reese¹, E. Blumberg¹, P. Abt¹, R. Bloom¹, K. Reddy¹, V. Holzmayer², K. Coller², M. Kuhns², G. Cloherty², D. Goldberg¹
¹University of Pennsylvania, Philadelphia, PA, ²Abbott Labs, Chicago, IL
*Purpose: The opioid epidemic has increased the number of deceased donors with active (Ab+/NAT+) or prior (Ab+/NAT-) HCV infection. Increased utilization of these donor organs…
2019 American Transplant Congress
Renal Outcomes from Expander-1: Pilot Study of HCV+ Donor Kidneys for HCV- Kidney Recipients
S. Thaduri¹, C. Durand¹, N. Desai², D. Segev², N. Bair¹, D. Brown¹, F. F. Naqvi¹
¹Medicine, -Johns Hopkins University, -Baltimore, MD, ²Surgery, -Johns Hopkins University, -Baltimore, MD
*Purpose: Direct acting antivirals (DAAs) have led to high cure rates (>95%) for hepatitis C. Utilization of HCV+ donor kidneys for patients with advanced kidney…
2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
C. Durand, B. Barnaba, D. Brown, N. Bair, F. Naqvi, M. Bowring, D. Segev, M. Sulkowski, N. Desai
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…
2019 American Transplant Congress
Results from the LIVE-C Free Trial
J. N. Fleming¹, D. DuBay¹, N. L. Jonassaint², R. S. Satoskar³, K. D. Chavin⁴
¹Medical University of South Carolina, Charleston, SC, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Medstar Georgetown Medical Center, Washington, DC, ⁴University Hospital, Cleveland, OH
*Purpose: Ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) has shown excellent results post-liver transplant. However, due to the poor tolerability of RBV, it is commonly…
2019 American Transplant Congress
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious
P. Brown¹, Z. Demertzis¹, S. Jafri²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI
*Purpose: Chronic HCV is one of the leading causes for end stage liver disease and liver transplantation. Since their introduction, DAAs have revolutionized the treatment…
2019 American Transplant Congress
Impact of Donor Hepatitis C Virus Infection on Kidney Transplant Outcomes in the Direct Acting Antiretroviral Era: Time to Revise the KDPI?
R. M. Cannon, E. G. Davis, L. Mackelaite, H. Dave, M. Eng, C. M. Jones
University of Louisville, Louisville, KY
*Purpose: The kidney donor risk index (KDRI), upon which the kidney donor profile index (KDPI) used for renal allocation is based, was derived before the…